GMAB
Income statement / Annual
Last year (2024), Genmab A/S's total revenue was $21.53 B,
an increase of 30.67% from the previous year.
In 2024, Genmab A/S's net income was $7.84 B.
See Genmab A/S,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$21.53 B |
$16.47 B |
$14.60 B |
$8.48 B |
$10.11 B |
$5.37 B |
$3.03 B |
$2.37 B |
$1.82 B |
$1.13 B |
| Cost of Revenue |
$985.00 M
|
$226.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$20.54 B
|
$16.25 B
|
$14.60 B
|
$8.48 B
|
$10.11 B
|
$5.37 B
|
$3.03 B
|
$2.37 B
|
$1.82 B
|
$1.13 B
|
| Gross Profit Ratio |
0.95
|
0.99
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$9.75 B
|
$7.63 B
|
$5.56 B
|
$4.18 B
|
$3.14 B
|
$2.39 B
|
$1.43 B
|
$874.28 M
|
$660.88 M
|
$487.66 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
$91.22 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.79 B
|
$3.30 B
|
$2.68 B
|
$1.28 B
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
$91.22 M
|
| Other Expenses |
$300.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$176.22 M
|
| Operating Expenses |
$13.84 B
|
$10.93 B
|
$8.24 B
|
$5.46 B
|
$3.80 B
|
$2.73 B
|
$1.64 B
|
$1.02 B
|
$763.29 M
|
$402.66 M
|
| Cost And Expenses |
$14.82 B
|
$11.15 B
|
$8.24 B
|
$5.46 B
|
$3.80 B
|
$2.73 B
|
$1.64 B
|
$1.02 B
|
$763.29 M
|
$402.66 M
|
| Interest Income |
$995.00 M
|
$939.00 M
|
$324.00 M
|
$197.00 M
|
$184.00 M
|
$120.00 M
|
$62.92 M
|
$41.43 M
|
$32.58 M
|
$37.26 M
|
| Interest Expense |
$120.00 M
|
$27.00 M
|
$21.00 M
|
$13.00 M
|
$10.00 M
|
$7.00 M
|
$417,000.00
|
$2.80 M
|
$213,000.00
|
$118,000.00
|
| Depreciation & Amortization |
$413.00 M
|
$240.00 M
|
$290.00 M
|
$250.00 M
|
$246.00 M
|
$139.00 M
|
$87.70 M
|
$47.54 M
|
$40.96 M
|
$31.82 M
|
| EBITDA |
$7.39 B |
$5.56 B |
$7.04 B |
$3.15 B |
$6.54 B |
$2.78 B |
$1.47 B |
$1.49 B |
$1.09 B |
$585.98 M |
| EBITDA Ratio |
0.34
|
0.34
|
0.48
|
0.41
|
0.67
|
0.54
|
0.56
|
0.48
|
0.64
|
0.7
|
| Operating Income Ratio |
0.31
|
0.32
|
0.44
|
0.36
|
0.62
|
0.49
|
0.46
|
0.57
|
0.58
|
0.64
|
| Total Other Income/Expenses Net |
$2.46 B
|
$316.00 M
|
$768.00 M
|
$965.00 M
|
-$409.00 M
|
$221.00 M
|
$231.69 M
|
-$280.45 M
|
$77.38 M
|
$27.15 M
|
| Income Before Tax |
$9.16 B
|
$5.64 B
|
$7.04 B
|
$3.98 B
|
$5.90 B
|
$2.86 B
|
$1.61 B
|
$1.06 B
|
$1.13 B
|
$757.53 M
|
| Income Before Tax Ratio |
0.43
|
0.34
|
0.48
|
0.47
|
0.58
|
0.53
|
0.53
|
0.45
|
0.62
|
0.67
|
| Income Tax Expense |
$1.32 B
|
$1.29 B
|
$1.51 B
|
$975.00 M
|
$1.15 B
|
$693.00 M
|
$139.83 M
|
-$39.83 M
|
-$56.86 M
|
-$5.99 M
|
| Net Income |
$7.84 B
|
$4.35 B
|
$5.45 B
|
$2.96 B
|
$4.76 B
|
$2.17 B
|
$1.47 B
|
$1.10 B
|
$1.19 B
|
$763.51 M
|
| Net Income Ratio |
0.36
|
0.26
|
0.37
|
0.35
|
0.47
|
0.4
|
0.49
|
0.47
|
0.65
|
0.67
|
| EPS |
121.36 |
66.02 |
83.4 |
45.2 |
73 |
34.4 |
24 |
18.1 |
19.8 |
13.1 |
| EPS Diluted |
121.36 |
66.02 |
82.6 |
44.8 |
72.2 |
34 |
23.7 |
17.8 |
19.2 |
12.6 |
| Weighted Average Shares Out |
$64.63 M
|
$65.92 M
|
$65.39 M
|
$65.40 M
|
$65.18 M
|
$62.96 M
|
$61.27 M
|
$60.83 M
|
$59.88 M
|
$58.52 M
|
| Weighted Average Shares Out Diluted |
$64.63 M
|
$65.91 M
|
$66.01 M
|
$66.05 M
|
$65.89 M
|
$63.64 M
|
$62.04 M
|
$62.09 M
|
$61.77 M
|
$60.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
